Functional lipidomics: Lysophosphatidic acid as a target for molecular diagnosis and therapy of ovarian cancer

Janos L. Tanyi, David Crotzer, Judith Wolf, Shuangxing Yu, Yutaka Hasegawa, John Lahad, Kwai Wa Cheng, Makiko Umezu-Goto, Glenn D. Prestwich, Andrew Morris, Robert A. Newman, Edward A. Felix, Rose Lapis, Gordon Mills

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

Epithelial ovarian cancer has the highest mortality rate of all gynecologic malignancies owing to late diagnosis and a lack of effective tumor-specific therapeutics. Ovarian carcinogenesis and metastasis occurs as a consequence of an orchestrated cascade of genetic, molecular, and biochemical events. Indeed, over the last several years, an extensive array of aberrations have been identified in this tumor; however, their roles in the pathophysiology of ovarian cancer remain to be elucidated. Abnormal lysophosphatidic acid (LPA) production, receptor expression, and signaling are frequently found in ovarian cancers, suggesting that LPA plays a role in the pathophysiology of the disease. Although LPA is the simplest lipid found in nature, it contains a number of structure components providing important informational content. High-affinity LPA receptors of the G-protein-coupled receptor family provide evidence for the importance of the molecule in normal cellular functions. LPA levels and the levels of related lysopholipids have been reported to be elevated in patient fluids including ascitic fluid and peripheral blood. The recent identification of the enzymes that mediate the degradation and production of LPA and the development of receptor-selective analogs may lead to new approaches in the treatment of this deadly disease. The LPA pathway may contain novel molecular targets, illustrating the potential role of functional lipidomics in the development of new therapeutic and diagnostic strategies for disease management.

Original languageEnglish (US)
Title of host publicationFunctional Lipidomics
PublisherCRC Press
Pages101-123
Number of pages23
ISBN (Electronic)9781420027655
ISBN (Print)9781574444674
DOIs
StatePublished - Jan 1 2005
Externally publishedYes

Fingerprint

ovarian neoplasms
Lysophosphatidic Acid Receptors
Ovarian Neoplasms
therapeutics
Acids
acids
Molecular Biology
Neoplasms
pathophysiology
Tumors
Ascitic Fluid
Delayed Diagnosis
molecular genetics
Therapeutics
receptors
Disease Management
G-Protein-Coupled Receptors
Carcinogenesis
Fluids
neoplasms

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Engineering(all)
  • Agricultural and Biological Sciences(all)
  • Medicine(all)

Cite this

Tanyi, J. L., Crotzer, D., Wolf, J., Yu, S., Hasegawa, Y., Lahad, J., ... Mills, G. (2005). Functional lipidomics: Lysophosphatidic acid as a target for molecular diagnosis and therapy of ovarian cancer. In Functional Lipidomics (pp. 101-123). CRC Press. https://doi.org/10.1201/9781420027655

Functional lipidomics : Lysophosphatidic acid as a target for molecular diagnosis and therapy of ovarian cancer. / Tanyi, Janos L.; Crotzer, David; Wolf, Judith; Yu, Shuangxing; Hasegawa, Yutaka; Lahad, John; Wa Cheng, Kwai; Umezu-Goto, Makiko; Prestwich, Glenn D.; Morris, Andrew; Newman, Robert A.; Felix, Edward A.; Lapis, Rose; Mills, Gordon.

Functional Lipidomics. CRC Press, 2005. p. 101-123.

Research output: Chapter in Book/Report/Conference proceedingChapter

Tanyi, JL, Crotzer, D, Wolf, J, Yu, S, Hasegawa, Y, Lahad, J, Wa Cheng, K, Umezu-Goto, M, Prestwich, GD, Morris, A, Newman, RA, Felix, EA, Lapis, R & Mills, G 2005, Functional lipidomics: Lysophosphatidic acid as a target for molecular diagnosis and therapy of ovarian cancer. in Functional Lipidomics. CRC Press, pp. 101-123. https://doi.org/10.1201/9781420027655
Tanyi JL, Crotzer D, Wolf J, Yu S, Hasegawa Y, Lahad J et al. Functional lipidomics: Lysophosphatidic acid as a target for molecular diagnosis and therapy of ovarian cancer. In Functional Lipidomics. CRC Press. 2005. p. 101-123 https://doi.org/10.1201/9781420027655
Tanyi, Janos L. ; Crotzer, David ; Wolf, Judith ; Yu, Shuangxing ; Hasegawa, Yutaka ; Lahad, John ; Wa Cheng, Kwai ; Umezu-Goto, Makiko ; Prestwich, Glenn D. ; Morris, Andrew ; Newman, Robert A. ; Felix, Edward A. ; Lapis, Rose ; Mills, Gordon. / Functional lipidomics : Lysophosphatidic acid as a target for molecular diagnosis and therapy of ovarian cancer. Functional Lipidomics. CRC Press, 2005. pp. 101-123
@inbook{00d9b1f9a9de408aae3919aa07ea9c92,
title = "Functional lipidomics: Lysophosphatidic acid as a target for molecular diagnosis and therapy of ovarian cancer",
abstract = "Epithelial ovarian cancer has the highest mortality rate of all gynecologic malignancies owing to late diagnosis and a lack of effective tumor-specific therapeutics. Ovarian carcinogenesis and metastasis occurs as a consequence of an orchestrated cascade of genetic, molecular, and biochemical events. Indeed, over the last several years, an extensive array of aberrations have been identified in this tumor; however, their roles in the pathophysiology of ovarian cancer remain to be elucidated. Abnormal lysophosphatidic acid (LPA) production, receptor expression, and signaling are frequently found in ovarian cancers, suggesting that LPA plays a role in the pathophysiology of the disease. Although LPA is the simplest lipid found in nature, it contains a number of structure components providing important informational content. High-affinity LPA receptors of the G-protein-coupled receptor family provide evidence for the importance of the molecule in normal cellular functions. LPA levels and the levels of related lysopholipids have been reported to be elevated in patient fluids including ascitic fluid and peripheral blood. The recent identification of the enzymes that mediate the degradation and production of LPA and the development of receptor-selective analogs may lead to new approaches in the treatment of this deadly disease. The LPA pathway may contain novel molecular targets, illustrating the potential role of functional lipidomics in the development of new therapeutic and diagnostic strategies for disease management.",
author = "Tanyi, {Janos L.} and David Crotzer and Judith Wolf and Shuangxing Yu and Yutaka Hasegawa and John Lahad and {Wa Cheng}, Kwai and Makiko Umezu-Goto and Prestwich, {Glenn D.} and Andrew Morris and Newman, {Robert A.} and Felix, {Edward A.} and Rose Lapis and Gordon Mills",
year = "2005",
month = "1",
day = "1",
doi = "10.1201/9781420027655",
language = "English (US)",
isbn = "9781574444674",
pages = "101--123",
booktitle = "Functional Lipidomics",
publisher = "CRC Press",

}

TY - CHAP

T1 - Functional lipidomics

T2 - Lysophosphatidic acid as a target for molecular diagnosis and therapy of ovarian cancer

AU - Tanyi, Janos L.

AU - Crotzer, David

AU - Wolf, Judith

AU - Yu, Shuangxing

AU - Hasegawa, Yutaka

AU - Lahad, John

AU - Wa Cheng, Kwai

AU - Umezu-Goto, Makiko

AU - Prestwich, Glenn D.

AU - Morris, Andrew

AU - Newman, Robert A.

AU - Felix, Edward A.

AU - Lapis, Rose

AU - Mills, Gordon

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Epithelial ovarian cancer has the highest mortality rate of all gynecologic malignancies owing to late diagnosis and a lack of effective tumor-specific therapeutics. Ovarian carcinogenesis and metastasis occurs as a consequence of an orchestrated cascade of genetic, molecular, and biochemical events. Indeed, over the last several years, an extensive array of aberrations have been identified in this tumor; however, their roles in the pathophysiology of ovarian cancer remain to be elucidated. Abnormal lysophosphatidic acid (LPA) production, receptor expression, and signaling are frequently found in ovarian cancers, suggesting that LPA plays a role in the pathophysiology of the disease. Although LPA is the simplest lipid found in nature, it contains a number of structure components providing important informational content. High-affinity LPA receptors of the G-protein-coupled receptor family provide evidence for the importance of the molecule in normal cellular functions. LPA levels and the levels of related lysopholipids have been reported to be elevated in patient fluids including ascitic fluid and peripheral blood. The recent identification of the enzymes that mediate the degradation and production of LPA and the development of receptor-selective analogs may lead to new approaches in the treatment of this deadly disease. The LPA pathway may contain novel molecular targets, illustrating the potential role of functional lipidomics in the development of new therapeutic and diagnostic strategies for disease management.

AB - Epithelial ovarian cancer has the highest mortality rate of all gynecologic malignancies owing to late diagnosis and a lack of effective tumor-specific therapeutics. Ovarian carcinogenesis and metastasis occurs as a consequence of an orchestrated cascade of genetic, molecular, and biochemical events. Indeed, over the last several years, an extensive array of aberrations have been identified in this tumor; however, their roles in the pathophysiology of ovarian cancer remain to be elucidated. Abnormal lysophosphatidic acid (LPA) production, receptor expression, and signaling are frequently found in ovarian cancers, suggesting that LPA plays a role in the pathophysiology of the disease. Although LPA is the simplest lipid found in nature, it contains a number of structure components providing important informational content. High-affinity LPA receptors of the G-protein-coupled receptor family provide evidence for the importance of the molecule in normal cellular functions. LPA levels and the levels of related lysopholipids have been reported to be elevated in patient fluids including ascitic fluid and peripheral blood. The recent identification of the enzymes that mediate the degradation and production of LPA and the development of receptor-selective analogs may lead to new approaches in the treatment of this deadly disease. The LPA pathway may contain novel molecular targets, illustrating the potential role of functional lipidomics in the development of new therapeutic and diagnostic strategies for disease management.

UR - http://www.scopus.com/inward/record.url?scp=33746908110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746908110&partnerID=8YFLogxK

U2 - 10.1201/9781420027655

DO - 10.1201/9781420027655

M3 - Chapter

AN - SCOPUS:33746908110

SN - 9781574444674

SP - 101

EP - 123

BT - Functional Lipidomics

PB - CRC Press

ER -